Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

114.96
-2.0400-1.74%
Post-market: 114.960.00000.00%19:30 EDT
Volume:574.19K
Turnover:66.17M
Market Cap:9.56B
PE:-35.79
High:119.93
Open:118.40
Low:113.74
Close:117.00
52wk High:130.05
52wk Low:45.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.92
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.33
PE(LYR):-31.15

Loading ...

Kymera Therapeutics Names Felix Baker Board Chairman, Replacing Bruce Booth

Reuters
·
Jun 25

Kymera Therapeutics Appoints Felix J. Baker, Ph.d., as Chairman of the Board of Directors

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Chief Business Officer Noah Goodman reports sale of 2,500 shares worth $247,500

Reuters
·
Jun 23

Kymera Therapeutics (KYMR) Receives a Buy from Barclays

TIPRANKS
·
Jun 22

Kymera Therapeutics participates in a conference call with JPMorgan

TIPRANKS
·
Jun 18

Why Kymera Therapeutics (KYMR) Is Up 16.6% After Positive KT-621 Phase 1 Japanese Data

Simply Wall St.
·
Jun 16

Kymera reports Phase 1 data in healthy Japanese adults for KT-621 oral STAT6 degrader

Reuters
·
Jun 12

Kymera Therapeutics posts corporate presentation outlining oral immunology protein degrader pipeline

Reuters
·
Jun 09

Kymera Therapeutics, Sanofi dose first participant in Phase 1 trial of IRAK4 degrader KT-485

Reuters
·
Jun 09

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral Irak4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics - Eligible for up to $975 Mln in KT-485 Milestones

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics - Receive S $20 Mln Milestone Payment From Sanofi

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics: Buy Rating Reiterated as Analyst Maintains $110 Price Target on Emerging Protein Degrader Pipeline

TIPRANKS
·
Jun 09

Kymera Therapeutics COO Chadwick to Retire

Dow Jones
·
Jun 09

Kymera Therapeutics COO Resigns, Transition Plan Implemented

TIPRANKS
·
Jun 09

Kymera Therapeutics names Penny Carlson SVP, Development Operations

Reuters
·
Jun 09

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

GlobeNewswire
·
Jun 08

Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease

TIPRANKS
·
Jun 06

A Look At Kymera Therapeutics (KYMR) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Jun 04